For the year ending 2025-12-31, AMLX had $148,799K increase in cash & cash equivalents over the period. -$123,481K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -144,735 |
| Stock-based compensation expense | 27,645 |
| Depreciation expense | 525 |
| Accretion of investment discounts, net | 5,526 |
| Other non-cash items | 169 |
| Accounts receivable, net | -359 |
| Interest receivable | -24 |
| Prepaid expenses and other current assets | -5,960 |
| Operating lease right-of-use assets | 1,730 |
| Deposits and other assets | 1,976 |
| Accounts payable | 580 |
| Accrued expenses | -6,598 |
| Operating lease liabilities | -1,162 |
| Net cash used in operating activities | -123,343 |
| Purchases of property and equipment | 138 |
| Purchases of investments | 231,823 |
| Proceeds from maturities of marketable securities | 246,000 |
| Net cash provided by investing activities | 14,039 |
| Proceeds from financings, net of issuance costs | 256,313 |
| Proceeds from exercise of stock options and rsus vesting | 4,077 |
| Withholding taxes paid on stock-based awards | 3,361 |
| Net cash provided by financing activities | 257,029 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | 1,074 |
| Net increase (decrease) increase in cash, cash equivalents and restricted cash equivalents | 148,799 |
| Cash, cash equivalents and restricted cash equivalents, beginning of year | 78,837 |
| Cash, cash equivalents and restricted cash equivalents, end of year | 227,636 |
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)